MYC and central nervous system cancer: Trametinib (MAPK inhibitor) binds and inactivates PKM2, reducing the levels of nuclear PKM through the suppression of the PKM2/c-myc axis, blocking the glycolysis, migration, and invasion in glioma cells [145].